<DOC>
	<DOCNO>NCT01572129</DOCNO>
	<brief_summary>Patients develop acute coronary syndrome despite dual antiplatelet therapy aspirin clopidogrel may benefit dose clopidogrel percutaneous coronary intervention . The aim study evaluate safety effectiveness clopidogrel reload patient chronic clopidogrel therapy acute coronary syndrome undergo percutaneous coronary intervention .</brief_summary>
	<brief_title>Clopidogrel Reloading Patients With NSTEACS Undergoing Percutaneous Coronary Intervention Chronic Clopidogrel Therapy</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>chronic ( &gt; 10 day ) therapy clopidogrel ( 75 mg/day ) nonSTsegment elevation acute coronary syndrome ( ACS ) require early diagnostic angiography primary percutaneous coronary intervention ( PCI ) acute STsegment elevation acute myocardial infarction platelet count &lt; 70 Ã— 10^9/L high bleeding risk coronary bypass graft previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>